Global Inactivated Mycoplasma Hyopneumoniae Vaccine Supply, Demand and Key Producers, 2026-2032
The global Inactivated Mycoplasma Hyopneumoniae Vaccine market size is expected to reach $ 967 million by 2032, rising at a market growth of 4.6% CAGR during the forecast period (2026-2032).
Inactivated Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product based on inactivated Mycoplasma hyopneumoniae antigen. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of enzootic pneumonia-related coughing, lung lesions, secondary infections and production performance losses. The product is usually supplied as an injectable emulsion or suspension, covering both monovalent inactivated vaccines and combination inactivated vaccines containing antigens such as porcine circovirus type 2. Key upstream materials include production strains, dedicated culture media, inactivating agents, adjuvants, buffers, stabilizers, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. On an ex-factory basis, global effective capacity of this product category is estimated at around 1.34 billion doses in 2025, with sales volume of approximately 1.083 billion doses and an average ex-factory price of about USD 0.63 per dose. The industry gross margin in 2025 is estimated at roughly 45%–65%, with multinational brands and multivalent vaccines usually at the upper end of the range, and local monovalent or regional products more commonly positioned in the middle to lower part of the range.
The market for inactivated Mycoplasma Hyopneumoniae Vaccine has established a mature application base, with demand mainly supported by the long-term need for integrated respiratory disease control in commercial swine farms. As pig farming continues to move toward larger-scale, more intensive and more standardized management, farms are placing greater emphasis on stable vaccination programs, vaccine safety and herd-level protection. The product is widely used in piglet and nursery-stage immunization and serves not only as a basic preventive vaccine but also as an important management tool to reduce respiratory problems during the growing-finishing stage. Current competition is no longer limited to monovalent vaccine pricing, but is increasingly shaped by product stability, duration of immunity, farm service capability and the value of integrated health solutions.
Looking ahead, combination vaccines and one-shot immunization programs are expected to gain further importance, especially products linked with the prevention needs of porcine circovirus, bacterial respiratory pathogens and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. At the same time, adjuvant systems, antigen purification, strain adaptability and batch-to-batch consistency will become key directions for product upgrading, driving the industry from traditional monovalent vaccine competition toward higher-quality combination vaccines and scenario-based immunization programs.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, its long-term impact on feed conversion, average daily gain, lung lesions and secondary infections can create hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, product consistency and whole-cycle herd health value, rather than purchase price alone.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of combination vaccines may also limit market penetration. Meanwhile, new vaccine routes, differences in local strains, regulatory approval requirements and cold-chain distribution conditions add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
This report studies the global Inactivated Mycoplasma Hyopneumoniae Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Inactivated Mycoplasma Hyopneumoniae Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Inactivated Mycoplasma Hyopneumoniae Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Inactivated Mycoplasma Hyopneumoniae Vaccine total production and demand, 2021-2032, (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine total production value, 2021-2032, (USD Million)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine domestic production, consumption, key domestic manufacturers and share
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Inactivated Mycoplasma Hyopneumoniae Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Boehringer Ingelheim, Merck Animal Health, Ceva Sant? Animale, HIPRA, Bioveta, Vaxxinova, Nisseiken, Kyoto Biken Laboratories, Pulike Biological Engineering, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Inactivated Mycoplasma Hyopneumoniae Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market, By Region:
1. How big is the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
2. What is the demand of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
3. What is the year over year growth of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
4. What is the production and production value of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
5. Who are the key producers in the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
6. What are the growth factors driving the market demand?
Inactivated Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product based on inactivated Mycoplasma hyopneumoniae antigen. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of enzootic pneumonia-related coughing, lung lesions, secondary infections and production performance losses. The product is usually supplied as an injectable emulsion or suspension, covering both monovalent inactivated vaccines and combination inactivated vaccines containing antigens such as porcine circovirus type 2. Key upstream materials include production strains, dedicated culture media, inactivating agents, adjuvants, buffers, stabilizers, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. On an ex-factory basis, global effective capacity of this product category is estimated at around 1.34 billion doses in 2025, with sales volume of approximately 1.083 billion doses and an average ex-factory price of about USD 0.63 per dose. The industry gross margin in 2025 is estimated at roughly 45%–65%, with multinational brands and multivalent vaccines usually at the upper end of the range, and local monovalent or regional products more commonly positioned in the middle to lower part of the range.
The market for inactivated Mycoplasma Hyopneumoniae Vaccine has established a mature application base, with demand mainly supported by the long-term need for integrated respiratory disease control in commercial swine farms. As pig farming continues to move toward larger-scale, more intensive and more standardized management, farms are placing greater emphasis on stable vaccination programs, vaccine safety and herd-level protection. The product is widely used in piglet and nursery-stage immunization and serves not only as a basic preventive vaccine but also as an important management tool to reduce respiratory problems during the growing-finishing stage. Current competition is no longer limited to monovalent vaccine pricing, but is increasingly shaped by product stability, duration of immunity, farm service capability and the value of integrated health solutions.
Looking ahead, combination vaccines and one-shot immunization programs are expected to gain further importance, especially products linked with the prevention needs of porcine circovirus, bacterial respiratory pathogens and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. At the same time, adjuvant systems, antigen purification, strain adaptability and batch-to-batch consistency will become key directions for product upgrading, driving the industry from traditional monovalent vaccine competition toward higher-quality combination vaccines and scenario-based immunization programs.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, its long-term impact on feed conversion, average daily gain, lung lesions and secondary infections can create hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, product consistency and whole-cycle herd health value, rather than purchase price alone.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of combination vaccines may also limit market penetration. Meanwhile, new vaccine routes, differences in local strains, regulatory approval requirements and cold-chain distribution conditions add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
This report studies the global Inactivated Mycoplasma Hyopneumoniae Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Inactivated Mycoplasma Hyopneumoniae Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Inactivated Mycoplasma Hyopneumoniae Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Inactivated Mycoplasma Hyopneumoniae Vaccine total production and demand, 2021-2032, (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine total production value, 2021-2032, (USD Million)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine domestic production, consumption, key domestic manufacturers and share
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Inactivated Mycoplasma Hyopneumoniae Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Inactivated Mycoplasma Hyopneumoniae Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Boehringer Ingelheim, Merck Animal Health, Ceva Sant? Animale, HIPRA, Bioveta, Vaxxinova, Nisseiken, Kyoto Biken Laboratories, Pulike Biological Engineering, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Inactivated Mycoplasma Hyopneumoniae Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Single Vaccine
- Dual Vaccine
- Others
- Oil-adjuvanted
- Aqueous-adjuvanted
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20–50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Pig Farming Groups
- Breeding Pig Farms
- Animal Health Service Providers
- Others
- Zoetis
- Boehringer Ingelheim
- Merck Animal Health
- Ceva Sant? Animale
- HIPRA
- Bioveta
- Vaxxinova
- Nisseiken
- Kyoto Biken Laboratories
- Pulike Biological Engineering
- Wuhan Keqian Biology
- Huapai Biotechnology
- TianKang Pharmaceutical
- Qilu Animal Health
1. How big is the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
2. What is the demand of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
3. What is the year over year growth of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
4. What is the production and production value of the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
5. Who are the key producers in the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Introduction
1.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Supply & Forecast
1.2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.2.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Pricing Trends (2021-2032)
1.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (Based on Production Site)
1.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021-2032)
1.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2021-2032)
1.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2032)
1.3.4 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.5 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.6 China Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.7 Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Demand (2021-2032)
2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region
2.2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region (2021-2026)
2.2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.4 China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.5 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.6 Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.7 South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.8 ASEAN Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.9 India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Manufacturer (2021-2026)
3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026)
3.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
3.6 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Overall Company Footprint Analysis
3.6.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Region Footprint
3.6.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
3.6.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison
4.1.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison
4.2.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison
4.3.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
4.5 China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share
4.5.1 China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
4.6 Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Single Vaccine
5.2.2 Dual Vaccine
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2021-2032)
5.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2021-2032)
5.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADJUVANT TYPE
6.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Adjuvant Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Adjuvant Type
6.2.1 Oil-adjuvanted
6.2.2 Aqueous-adjuvanted
6.2.3 Others
6.3 Market Segment by Adjuvant Type
6.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2021-2032)
6.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2021-2032)
6.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2032)
7 MARKET ANALYSIS BY DOSE PACK SIZE
7.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Dose Pack Size: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dose Pack Size
7.2.1 Small Pack (Below 20 Doses per Vial)
7.2.2 Medium Pack (20–50 Doses per Vial)
7.2.3 Large Pack (Above 50 Doses per Vial)
7.3 Market Segment by Dose Pack Size
7.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2021-2032)
7.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2021-2032)
7.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Large-scale Pig Farming Groups
8.2.2 Breeding Pig Farms
8.2.3 Animal Health Service Providers
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2021-2032)
8.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2021-2032)
8.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Zoetis
9.1.1 Zoetis Details
9.1.2 Zoetis Major Business
9.1.3 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.1.4 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Zoetis Recent Developments/Updates
9.1.6 Zoetis Competitive Strengths & Weaknesses
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Details
9.2.2 Boehringer Ingelheim Major Business
9.2.3 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.2.4 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Boehringer Ingelheim Recent Developments/Updates
9.2.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.3 Merck Animal Health
9.3.1 Merck Animal Health Details
9.3.2 Merck Animal Health Major Business
9.3.3 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.3.4 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Merck Animal Health Recent Developments/Updates
9.3.6 Merck Animal Health Competitive Strengths & Weaknesses
9.4 Ceva Sant? Animale
9.4.1 Ceva Sant? Animale Details
9.4.2 Ceva Sant? Animale Major Business
9.4.3 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.4.4 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Ceva Sant? Animale Recent Developments/Updates
9.4.6 Ceva Sant? Animale Competitive Strengths & Weaknesses
9.5 HIPRA
9.5.1 HIPRA Details
9.5.2 HIPRA Major Business
9.5.3 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.5.4 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 HIPRA Recent Developments/Updates
9.5.6 HIPRA Competitive Strengths & Weaknesses
9.6 Bioveta
9.6.1 Bioveta Details
9.6.2 Bioveta Major Business
9.6.3 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.6.4 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Bioveta Recent Developments/Updates
9.6.6 Bioveta Competitive Strengths & Weaknesses
9.7 Vaxxinova
9.7.1 Vaxxinova Details
9.7.2 Vaxxinova Major Business
9.7.3 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.7.4 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Vaxxinova Recent Developments/Updates
9.7.6 Vaxxinova Competitive Strengths & Weaknesses
9.8 Nisseiken
9.8.1 Nisseiken Details
9.8.2 Nisseiken Major Business
9.8.3 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.8.4 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Nisseiken Recent Developments/Updates
9.8.6 Nisseiken Competitive Strengths & Weaknesses
9.9 Kyoto Biken Laboratories
9.9.1 Kyoto Biken Laboratories Details
9.9.2 Kyoto Biken Laboratories Major Business
9.9.3 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.9.4 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Kyoto Biken Laboratories Recent Developments/Updates
9.9.6 Kyoto Biken Laboratories Competitive Strengths & Weaknesses
9.10 Pulike Biological Engineering
9.10.1 Pulike Biological Engineering Details
9.10.2 Pulike Biological Engineering Major Business
9.10.3 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.10.4 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Pulike Biological Engineering Recent Developments/Updates
9.10.6 Pulike Biological Engineering Competitive Strengths & Weaknesses
9.11 Wuhan Keqian Biology
9.11.1 Wuhan Keqian Biology Details
9.11.2 Wuhan Keqian Biology Major Business
9.11.3 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.11.4 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Wuhan Keqian Biology Recent Developments/Updates
9.11.6 Wuhan Keqian Biology Competitive Strengths & Weaknesses
9.12 Huapai Biotechnology
9.12.1 Huapai Biotechnology Details
9.12.2 Huapai Biotechnology Major Business
9.12.3 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.12.4 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Huapai Biotechnology Recent Developments/Updates
9.12.6 Huapai Biotechnology Competitive Strengths & Weaknesses
9.13 TianKang Pharmaceutical
9.13.1 TianKang Pharmaceutical Details
9.13.2 TianKang Pharmaceutical Major Business
9.13.3 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.13.4 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 TianKang Pharmaceutical Recent Developments/Updates
9.13.6 TianKang Pharmaceutical Competitive Strengths & Weaknesses
9.14 Qilu Animal Health
9.14.1 Qilu Animal Health Details
9.14.2 Qilu Animal Health Major Business
9.14.3 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.14.4 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Qilu Animal Health Recent Developments/Updates
9.14.6 Qilu Animal Health Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Chain
10.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Upstream Analysis
10.2.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Production Mode
10.6 Inactivated Mycoplasma Hyopneumoniae Vaccine Procurement Model
10.7 Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Sales Model and Sales Channels
10.7.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Model
10.7.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Introduction
1.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Supply & Forecast
1.2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.2.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Pricing Trends (2021-2032)
1.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (Based on Production Site)
1.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021-2032)
1.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2021-2032)
1.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2032)
1.3.4 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.5 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.6 China Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.3.7 Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Demand (2021-2032)
2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region
2.2.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region (2021-2026)
2.2.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.4 China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.5 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.6 Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.7 South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.8 ASEAN Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
2.9 India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Manufacturer (2021-2026)
3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026)
3.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
3.6 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Overall Company Footprint Analysis
3.6.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Region Footprint
3.6.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
3.6.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison
4.1.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison
4.2.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison
4.3.1 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
4.5 China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share
4.5.1 China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
4.6 Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Single Vaccine
5.2.2 Dual Vaccine
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2021-2032)
5.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2021-2032)
5.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADJUVANT TYPE
6.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Adjuvant Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Adjuvant Type
6.2.1 Oil-adjuvanted
6.2.2 Aqueous-adjuvanted
6.2.3 Others
6.3 Market Segment by Adjuvant Type
6.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2021-2032)
6.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2021-2032)
6.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2032)
7 MARKET ANALYSIS BY DOSE PACK SIZE
7.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Dose Pack Size: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dose Pack Size
7.2.1 Small Pack (Below 20 Doses per Vial)
7.2.2 Medium Pack (20–50 Doses per Vial)
7.2.3 Large Pack (Above 50 Doses per Vial)
7.3 Market Segment by Dose Pack Size
7.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2021-2032)
7.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2021-2032)
7.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Large-scale Pig Farming Groups
8.2.2 Breeding Pig Farms
8.2.3 Animal Health Service Providers
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2021-2032)
8.3.2 World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2021-2032)
8.3.3 World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Zoetis
9.1.1 Zoetis Details
9.1.2 Zoetis Major Business
9.1.3 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.1.4 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Zoetis Recent Developments/Updates
9.1.6 Zoetis Competitive Strengths & Weaknesses
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Details
9.2.2 Boehringer Ingelheim Major Business
9.2.3 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.2.4 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Boehringer Ingelheim Recent Developments/Updates
9.2.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.3 Merck Animal Health
9.3.1 Merck Animal Health Details
9.3.2 Merck Animal Health Major Business
9.3.3 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.3.4 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Merck Animal Health Recent Developments/Updates
9.3.6 Merck Animal Health Competitive Strengths & Weaknesses
9.4 Ceva Sant? Animale
9.4.1 Ceva Sant? Animale Details
9.4.2 Ceva Sant? Animale Major Business
9.4.3 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.4.4 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Ceva Sant? Animale Recent Developments/Updates
9.4.6 Ceva Sant? Animale Competitive Strengths & Weaknesses
9.5 HIPRA
9.5.1 HIPRA Details
9.5.2 HIPRA Major Business
9.5.3 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.5.4 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 HIPRA Recent Developments/Updates
9.5.6 HIPRA Competitive Strengths & Weaknesses
9.6 Bioveta
9.6.1 Bioveta Details
9.6.2 Bioveta Major Business
9.6.3 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.6.4 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Bioveta Recent Developments/Updates
9.6.6 Bioveta Competitive Strengths & Weaknesses
9.7 Vaxxinova
9.7.1 Vaxxinova Details
9.7.2 Vaxxinova Major Business
9.7.3 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.7.4 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Vaxxinova Recent Developments/Updates
9.7.6 Vaxxinova Competitive Strengths & Weaknesses
9.8 Nisseiken
9.8.1 Nisseiken Details
9.8.2 Nisseiken Major Business
9.8.3 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.8.4 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Nisseiken Recent Developments/Updates
9.8.6 Nisseiken Competitive Strengths & Weaknesses
9.9 Kyoto Biken Laboratories
9.9.1 Kyoto Biken Laboratories Details
9.9.2 Kyoto Biken Laboratories Major Business
9.9.3 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.9.4 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Kyoto Biken Laboratories Recent Developments/Updates
9.9.6 Kyoto Biken Laboratories Competitive Strengths & Weaknesses
9.10 Pulike Biological Engineering
9.10.1 Pulike Biological Engineering Details
9.10.2 Pulike Biological Engineering Major Business
9.10.3 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.10.4 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Pulike Biological Engineering Recent Developments/Updates
9.10.6 Pulike Biological Engineering Competitive Strengths & Weaknesses
9.11 Wuhan Keqian Biology
9.11.1 Wuhan Keqian Biology Details
9.11.2 Wuhan Keqian Biology Major Business
9.11.3 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.11.4 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Wuhan Keqian Biology Recent Developments/Updates
9.11.6 Wuhan Keqian Biology Competitive Strengths & Weaknesses
9.12 Huapai Biotechnology
9.12.1 Huapai Biotechnology Details
9.12.2 Huapai Biotechnology Major Business
9.12.3 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.12.4 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Huapai Biotechnology Recent Developments/Updates
9.12.6 Huapai Biotechnology Competitive Strengths & Weaknesses
9.13 TianKang Pharmaceutical
9.13.1 TianKang Pharmaceutical Details
9.13.2 TianKang Pharmaceutical Major Business
9.13.3 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.13.4 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 TianKang Pharmaceutical Recent Developments/Updates
9.13.6 TianKang Pharmaceutical Competitive Strengths & Weaknesses
9.14 Qilu Animal Health
9.14.1 Qilu Animal Health Details
9.14.2 Qilu Animal Health Major Business
9.14.3 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
9.14.4 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Qilu Animal Health Recent Developments/Updates
9.14.6 Qilu Animal Health Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Chain
10.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Upstream Analysis
10.2.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Production Mode
10.6 Inactivated Mycoplasma Hyopneumoniae Vaccine Procurement Model
10.7 Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Sales Model and Sales Channels
10.7.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Model
10.7.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2021-2026)
Table 9. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2027-2032)
Table 10. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Inactivated Mycoplasma Hyopneumoniae Vaccine Major Market Trends
Table 13. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Inactivated Mycoplasma Hyopneumoniae Vaccine Producers in 2025
Table 18. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Inactivated Mycoplasma Hyopneumoniae Vaccine Producers in 2025
Table 20. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Company Evaluation Quadrant
Table 22. World Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Inactivated Mycoplasma Hyopneumoniae Vaccine Production Site of Key Manufacturer
Table 24. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
Table 25. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
Table 26. Inactivated Mycoplasma Hyopneumoniae Vaccine Competitive Factors
Table 27. Inactivated Mycoplasma Hyopneumoniae Vaccine New Entrant and Capacity Expansion Plans
Table 28. Inactivated Mycoplasma Hyopneumoniae Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 37. China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 47. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Table 55. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2021-2026) & (K Dose)
Table 56. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2027-2032) & (K Dose)
Table 57. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2021-2026) & (USD Million)
Table 58. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2027-2032) & (USD Million)
Table 59. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2026) & (US$/Dose)
Table 60. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2027-2032) & (US$/Dose)
Table 61. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 62. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2021-2026) & (K Dose)
Table 63. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2027-2032) & (K Dose)
Table 64. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2021-2026) & (USD Million)
Table 65. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2027-2032) & (USD Million)
Table 66. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 67. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2027-2032) & (US$/Dose)
Table 68. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2021-2026) & (K Dose)
Table 70. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2027-2032) & (K Dose)
Table 71. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Zoetis Basic Information, Manufacturing Base and Competitors
Table 76. Zoetis Major Business
Table 77. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 78. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Zoetis Recent Developments/Updates
Table 80. Zoetis Competitive Strengths & Weaknesses
Table 81. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 82. Boehringer Ingelheim Major Business
Table 83. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 84. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Boehringer Ingelheim Recent Developments/Updates
Table 86. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 87. Merck Animal Health Basic Information, Manufacturing Base and Competitors
Table 88. Merck Animal Health Major Business
Table 89. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 90. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Merck Animal Health Recent Developments/Updates
Table 92. Merck Animal Health Competitive Strengths & Weaknesses
Table 93. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 94. Ceva Sant? Animale Major Business
Table 95. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 96. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Ceva Sant? Animale Recent Developments/Updates
Table 98. Ceva Sant? Animale Competitive Strengths & Weaknesses
Table 99. HIPRA Basic Information, Manufacturing Base and Competitors
Table 100. HIPRA Major Business
Table 101. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 102. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. HIPRA Recent Developments/Updates
Table 104. HIPRA Competitive Strengths & Weaknesses
Table 105. Bioveta Basic Information, Manufacturing Base and Competitors
Table 106. Bioveta Major Business
Table 107. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 108. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Bioveta Recent Developments/Updates
Table 110. Bioveta Competitive Strengths & Weaknesses
Table 111. Vaxxinova Basic Information, Manufacturing Base and Competitors
Table 112. Vaxxinova Major Business
Table 113. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 114. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Vaxxinova Recent Developments/Updates
Table 116. Vaxxinova Competitive Strengths & Weaknesses
Table 117. Nisseiken Basic Information, Manufacturing Base and Competitors
Table 118. Nisseiken Major Business
Table 119. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 120. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Nisseiken Recent Developments/Updates
Table 122. Nisseiken Competitive Strengths & Weaknesses
Table 123. Kyoto Biken Laboratories Basic Information, Manufacturing Base and Competitors
Table 124. Kyoto Biken Laboratories Major Business
Table 125. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 126. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Kyoto Biken Laboratories Recent Developments/Updates
Table 128. Kyoto Biken Laboratories Competitive Strengths & Weaknesses
Table 129. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 130. Pulike Biological Engineering Major Business
Table 131. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 132. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Pulike Biological Engineering Recent Developments/Updates
Table 134. Pulike Biological Engineering Competitive Strengths & Weaknesses
Table 135. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 136. Wuhan Keqian Biology Major Business
Table 137. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 138. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Wuhan Keqian Biology Recent Developments/Updates
Table 140. Wuhan Keqian Biology Competitive Strengths & Weaknesses
Table 141. Huapai Biotechnology Basic Information, Manufacturing Base and Competitors
Table 142. Huapai Biotechnology Major Business
Table 143. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 144. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Huapai Biotechnology Recent Developments/Updates
Table 146. Huapai Biotechnology Competitive Strengths & Weaknesses
Table 147. TianKang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. TianKang Pharmaceutical Major Business
Table 149. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 150. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. TianKang Pharmaceutical Recent Developments/Updates
Table 152. TianKang Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Qilu Animal Health Basic Information, Manufacturing Base and Competitors
Table 154. Qilu Animal Health Major Business
Table 155. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 156. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Qilu Animal Health Recent Developments/Updates
Table 158. Qilu Animal Health Competitive Strengths & Weaknesses
Table 159. Global Key Players of Inactivated Mycoplasma Hyopneumoniae Vaccine Upstream (Raw Materials)
Table 160. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
Table 161. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
Table 1. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2021-2026)
Table 9. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2027-2032)
Table 10. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Inactivated Mycoplasma Hyopneumoniae Vaccine Major Market Trends
Table 13. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Inactivated Mycoplasma Hyopneumoniae Vaccine Producers in 2025
Table 18. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Inactivated Mycoplasma Hyopneumoniae Vaccine Producers in 2025
Table 20. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Company Evaluation Quadrant
Table 22. World Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Inactivated Mycoplasma Hyopneumoniae Vaccine Production Site of Key Manufacturer
Table 24. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
Table 25. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
Table 26. Inactivated Mycoplasma Hyopneumoniae Vaccine Competitive Factors
Table 27. Inactivated Mycoplasma Hyopneumoniae Vaccine New Entrant and Capacity Expansion Plans
Table 28. Inactivated Mycoplasma Hyopneumoniae Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 37. China Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share (2021-2026)
Table 47. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Table 55. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2021-2026) & (K Dose)
Table 56. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Adjuvant Type (2027-2032) & (K Dose)
Table 57. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2021-2026) & (USD Million)
Table 58. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type (2027-2032) & (USD Million)
Table 59. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2026) & (US$/Dose)
Table 60. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2027-2032) & (US$/Dose)
Table 61. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 62. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2021-2026) & (K Dose)
Table 63. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Dose Pack Size (2027-2032) & (K Dose)
Table 64. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2021-2026) & (USD Million)
Table 65. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size (2027-2032) & (USD Million)
Table 66. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 67. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2027-2032) & (US$/Dose)
Table 68. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2021-2026) & (K Dose)
Table 70. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production by Application (2027-2032) & (K Dose)
Table 71. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Zoetis Basic Information, Manufacturing Base and Competitors
Table 76. Zoetis Major Business
Table 77. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 78. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Zoetis Recent Developments/Updates
Table 80. Zoetis Competitive Strengths & Weaknesses
Table 81. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 82. Boehringer Ingelheim Major Business
Table 83. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 84. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Boehringer Ingelheim Recent Developments/Updates
Table 86. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 87. Merck Animal Health Basic Information, Manufacturing Base and Competitors
Table 88. Merck Animal Health Major Business
Table 89. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 90. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Merck Animal Health Recent Developments/Updates
Table 92. Merck Animal Health Competitive Strengths & Weaknesses
Table 93. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 94. Ceva Sant? Animale Major Business
Table 95. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 96. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Ceva Sant? Animale Recent Developments/Updates
Table 98. Ceva Sant? Animale Competitive Strengths & Weaknesses
Table 99. HIPRA Basic Information, Manufacturing Base and Competitors
Table 100. HIPRA Major Business
Table 101. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 102. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. HIPRA Recent Developments/Updates
Table 104. HIPRA Competitive Strengths & Weaknesses
Table 105. Bioveta Basic Information, Manufacturing Base and Competitors
Table 106. Bioveta Major Business
Table 107. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 108. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Bioveta Recent Developments/Updates
Table 110. Bioveta Competitive Strengths & Weaknesses
Table 111. Vaxxinova Basic Information, Manufacturing Base and Competitors
Table 112. Vaxxinova Major Business
Table 113. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 114. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Vaxxinova Recent Developments/Updates
Table 116. Vaxxinova Competitive Strengths & Weaknesses
Table 117. Nisseiken Basic Information, Manufacturing Base and Competitors
Table 118. Nisseiken Major Business
Table 119. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 120. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Nisseiken Recent Developments/Updates
Table 122. Nisseiken Competitive Strengths & Weaknesses
Table 123. Kyoto Biken Laboratories Basic Information, Manufacturing Base and Competitors
Table 124. Kyoto Biken Laboratories Major Business
Table 125. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 126. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Kyoto Biken Laboratories Recent Developments/Updates
Table 128. Kyoto Biken Laboratories Competitive Strengths & Weaknesses
Table 129. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 130. Pulike Biological Engineering Major Business
Table 131. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 132. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Pulike Biological Engineering Recent Developments/Updates
Table 134. Pulike Biological Engineering Competitive Strengths & Weaknesses
Table 135. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 136. Wuhan Keqian Biology Major Business
Table 137. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 138. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Wuhan Keqian Biology Recent Developments/Updates
Table 140. Wuhan Keqian Biology Competitive Strengths & Weaknesses
Table 141. Huapai Biotechnology Basic Information, Manufacturing Base and Competitors
Table 142. Huapai Biotechnology Major Business
Table 143. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 144. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Huapai Biotechnology Recent Developments/Updates
Table 146. Huapai Biotechnology Competitive Strengths & Weaknesses
Table 147. TianKang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. TianKang Pharmaceutical Major Business
Table 149. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 150. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. TianKang Pharmaceutical Recent Developments/Updates
Table 152. TianKang Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Qilu Animal Health Basic Information, Manufacturing Base and Competitors
Table 154. Qilu Animal Health Major Business
Table 155. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 156. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Qilu Animal Health Recent Developments/Updates
Table 158. Qilu Animal Health Competitive Strengths & Weaknesses
Table 159. Global Key Players of Inactivated Mycoplasma Hyopneumoniae Vaccine Upstream (Raw Materials)
Table 160. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
Table 161. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
LIST OF FIGURES
Figure 1. Inactivated Mycoplasma Hyopneumoniae Vaccine Picture
Figure 2. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 9. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 10. China Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 11. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 12. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 15. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share by Region (2021-2032)
Figure 16. United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 17. China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 22. India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Inactivated Mycoplasma Hyopneumoniae Vaccine Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Inactivated Mycoplasma Hyopneumoniae Vaccine Markets in 2025
Figure 26. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 30. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 32. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Type in 2025
Figure 34. Single Vaccine
Figure 35. Dual Vaccine
Figure 36. Others
Figure 37. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Type (2021-2032)
Figure 38. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Type (2021-2032)
Figure 39. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Figure 41. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Adjuvant Type in 2025
Figure 42. Oil-adjuvanted
Figure 43. Aqueous-adjuvanted
Figure 44. Others
Figure 45. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Adjuvant Type (2021-2032)
Figure 46. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Adjuvant Type (2021-2032)
Figure 47. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2032) & (US$/Dose)
Figure 48. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 49. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Dose Pack Size in 2025
Figure 50. Small Pack (Below 20 Doses per Vial)
Figure 51. Medium Pack (20–50 Doses per Vial)
Figure 52. Large Pack (Above 50 Doses per Vial)
Figure 53. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Dose Pack Size (2021-2032)
Figure 54. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Dose Pack Size (2021-2032)
Figure 55. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2032) & (US$/Dose)
Figure 56. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 57. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Application in 2025
Figure 58. Large-scale Pig Farming Groups
Figure 59. Breeding Pig Farms
Figure 60. Animal Health Service Providers
Figure 61. Others
Figure 62. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Application (2021-2032)
Figure 63. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Application (2021-2032)
Figure 64. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 65. Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Chain
Figure 66. Inactivated Mycoplasma Hyopneumoniae Vaccine Procurement Model
Figure 67. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Model
Figure 68. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Channels, Direct Sales, and Distribution
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. Inactivated Mycoplasma Hyopneumoniae Vaccine Picture
Figure 2. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 9. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 10. China Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 11. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Production (2021-2032) & (K Dose)
Figure 12. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 15. World Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share by Region (2021-2032)
Figure 16. United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 17. China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 22. India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Inactivated Mycoplasma Hyopneumoniae Vaccine Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Inactivated Mycoplasma Hyopneumoniae Vaccine Markets in 2025
Figure 26. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 30. China Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share 2025
Figure 32. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Type in 2025
Figure 34. Single Vaccine
Figure 35. Dual Vaccine
Figure 36. Others
Figure 37. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Type (2021-2032)
Figure 38. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Type (2021-2032)
Figure 39. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Figure 41. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Adjuvant Type in 2025
Figure 42. Oil-adjuvanted
Figure 43. Aqueous-adjuvanted
Figure 44. Others
Figure 45. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Adjuvant Type (2021-2032)
Figure 46. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Adjuvant Type (2021-2032)
Figure 47. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Adjuvant Type (2021-2032) & (US$/Dose)
Figure 48. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 49. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Dose Pack Size in 2025
Figure 50. Small Pack (Below 20 Doses per Vial)
Figure 51. Medium Pack (20–50 Doses per Vial)
Figure 52. Large Pack (Above 50 Doses per Vial)
Figure 53. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Dose Pack Size (2021-2032)
Figure 54. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Dose Pack Size (2021-2032)
Figure 55. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Dose Pack Size (2021-2032) & (US$/Dose)
Figure 56. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 57. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Application in 2025
Figure 58. Large-scale Pig Farming Groups
Figure 59. Breeding Pig Farms
Figure 60. Animal Health Service Providers
Figure 61. Others
Figure 62. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Market Share by Application (2021-2032)
Figure 63. World Inactivated Mycoplasma Hyopneumoniae Vaccine Production Value Market Share by Application (2021-2032)
Figure 64. World Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 65. Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Chain
Figure 66. Inactivated Mycoplasma Hyopneumoniae Vaccine Procurement Model
Figure 67. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Model
Figure 68. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Channels, Direct Sales, and Distribution
Figure 69. Methodology
Figure 70. Research Process and Data Source
